SGN-B6A: A Vedotin Antibody-Drug Conjugate that Targets Integrin Beta-6 & Shows Clinical Efficacy in Multiple Solid Tumor Indications
Time: 11:00 am
day: Day Two
Details:
- Explore how sigvotatug vedotin (SV, SGN-B6A) is an investigational, first-in-class ADC, which shows high specificity towards integrin beta-6
- Overview of sigvotatug vedotin preclinical and clinical safety and efficacy data
- Discuss the rationale for clinical combination between sigvotatug vedotin and CPIs
